...
首页> 外文期刊>Der Pharmacia Lettre >Preparation and characterization of Irbesartan solid dispersion Tablet: MeltDispersion Technique for dissolution enhancement
【24h】

Preparation and characterization of Irbesartan solid dispersion Tablet: MeltDispersion Technique for dissolution enhancement

机译:厄贝沙坦固体分散片的制备与表征:提高溶出度的熔体分散技术

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Oral bioavailability of irbesartan (IBS) is only 60% due to its poor aqueous solubility and dissolution rate. The present research work was aimed for improvement of dissolution of IBS by melt dispersion technique which is supposed to improve oral bioavailability. Solid dispersions of IBS were prepared using polymeric additives (polyvinylpyrrolidone, copovidone, polyethylene glycol and poloxamer) in different ratios. Quantitative solubility of selected formulations were evaluated after a trial of physical solubility study of all the formulations. Formulation A [IBS/PVP (1:1) + poloxamer 10%] and formulation B [IBS/PVP (1:2) + poloxamer 5%] were taken for micronization by jet milling (Cadmach, Ahmedabad, india). Formulation A and B have been characterised by instrumental study such as particle size analysis (Sympatech particle size laser analyser, GmbH, Germany); XRD (Mettler Toledo, USA); DSC (Mettler Toledo, USA). Formulation A and B have been tableted (each tablet contains 150mg IBS) using Micro Crystalline Cellulose (MCC 102), as major filler by direct compression applying 100-120 N pressure. Solubility of A and B have been improved to 4.6 (.0055mg/ml) times and 3.8 (0.046mg/ml) times respectively compared to pure drug (0.012mg/mL). IBS dissolution of tablet A has been improved to 71.76% in SGF (0.1N HCl). Micronized particle size of A (X90:103μ) and B (X90:69μ), and amorphization of drug in Solid dispersions (decreased intensity of XRD and is appearance of endothermic peak of crystalline drug) have brought about improved dissolution.
机译:厄贝沙坦(IBS)的口服生物利用度由于水溶性和溶解速度较差而仅60%。目前的研究工作旨在通过熔体分散技术改善IBS的溶出度,该技术应提高口服生物利用度。使用不同比例的聚合物添加剂(聚乙烯吡咯烷酮,共聚维酮,聚乙二醇和泊洛沙姆)制备IBS的固体分散体。在对所有制剂进行物理溶解度研究后,评估了所选制剂的定量溶解度。通过喷射研磨(Cadmach,Ahmedab​​ad,印度)将制剂A [IBS / PVP(1:1)+泊洛沙姆10%]和制剂B [IBS / PVP(1:2)+泊洛沙姆5%]进行微粉化。制剂A和B已通过仪器研究,例如粒度分析(Sympatech粒度激光分析仪,德国GmbH)来表征。 XRD(美国梅特勒-托莱多); DSC(美国梅特勒-托莱多)。使用微晶纤维素(MCC 102)作为主要填充剂,通过直接施加100-120 N的压力,将制剂A和B制成片剂(每片含150mg IBS)。与纯药物(0.012mg / mL)相比,A和B的溶解度分别提高了4.6(.0055mg / ml)和3.8(0.046mg / ml)倍。在SGF(0.1N HCl)中,片剂A的IBS溶出度已提高至71.76%。 A(X90:103μ)和B(X90:69μ)的微粒化尺寸以及固体分散体中的药物非晶化(XRD强度降低和结晶药物的吸热峰出现)都改善了溶出度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号